Condition

Stage IV Non-Small Cell Lung Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 51 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials51
Recruiting1
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

51 shown
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung CancerNCT03199651 · 2017-07-17
RECRUITING
Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLCNCT07392073 · 2026-04-01
NOT_YET_RECRUITING
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerNCT04670445 · 2021-01-23
COMPLETED
Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation LoadsNCT03023904 · 2017-12-29
WITHDRAWN
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With CancerNCT03154190 · 2017-08-08
COMPLETED
Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung CancerNCT03121417 · 2017-07-21
WITHDRAWN
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT03048500 · 2017-07-12
UNKNOWN
Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung CancerNCT02947386 · 2017-06-29
COMPLETED
Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)NCT03176173 · 2017-06-28
COMPLETED
Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLCNCT02658097 · 2017-06-07
COMPLETED
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerNCT03137771 · 2017-04-07
ACTIVE_NOT_RECRUITING
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475NCT03049618 · 2017-03-10
COMPLETED
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic MutationsNCT02949843 · 2017-03-10
TERMINATED
TG4010 and Nivolumab in Patients With Lung CancerNCT02823990 · 2016-12-14
COMPLETED
Palbociclib With Cisplatin or Carboplatin in Advanced Solid TumorsNCT02897375 · 2016-10-24
COMPLETED
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)NCT02728596 · 2016-10-07
COMPLETED
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain MetastasesNCT02858869 · 2016-10-04
COMPLETED
Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung CancerNCT02879994 · 2016-09-15
COMPLETED
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung CancerNCT02581943 · 2016-06-17
COMPLETED
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission TomographyNCT02819024 · 2016-06-01
COMPLETED
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionNCT02567396 · 2016-06-01
WITHDRAWN
Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung CancerNCT02451865 · 2016-06-01
WITHDRAWN
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsNCT02650635 · 2016-02-05
TERMINATED
MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung CancerNCT02400814 · 2015-12-03
TERMINATED
Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by SurgeryNCT02566421 · 2015-10-01
TERMINATED
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to ErlotinibNCT02364609 · 2015-09-30
COMPLETED
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLCNCT02451930 · 2015-09-04
COMPLETED
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid TumorsNCT02495896 · 2015-09-03
ACTIVE_NOT_RECRUITING
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid TumorsNCT01971489 · 2015-09-01
WITHDRAWN
18F-FSPG PET/CT for Cancer Patients on TherapyNCT02599194 · 2015-07-01
COMPLETED
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerNCT02438722 · 2015-05-07
COMPLETED
Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3NCT02426658 · 2015-05-01
COMPLETED
Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerNCT02009436 · 2015-02-09
COMPLETED
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate CancerNCT02206334 · 2014-08-01
COMPLETED
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionNCT02134886 · 2014-07-01
TERMINATED
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung CancerNCT01737502 · 2014-05-14
COMPLETED
Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II TrialNCT02045446 · 2014-02-01
COMPLETED
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung CancerNCT02073968 · 2013-07-01
COMPLETED
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung CancerNCT01935947 · 2013-05-01
TERMINATED
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung CancerNCT01620190 · 2012-12-02
COMPLETED
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerNCT01193881 · 2010-08-01
TERMINATED
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsNCT01131234 · 2010-05-01
COMPLETED
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerNCT00955305 · 2010-03-01
TERMINATED
A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLCNCT00963807 · 2009-09-01
COMPLETED
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung CancerNCT00738881 · 2008-10-01
TERMINATED
Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung CancerNCT00602797 · 2007-12-17
COMPLETED
Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung MetastasisNCT01014598 · 2007-12-04
COMPLETED
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung CancerNCT00387465 · 2006-08-01
COMPLETED
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung CancerNCT00950365 · 2006-04-01
COMPLETED
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)NCT00088088 · 2004-03-01
COMPLETED
Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung CancerNCT01004731 · 2001-06-01
COMPLETED

Common interventions

Laboratory Biomarker AnalysisOTHER26Pharmacological StudyOTHER10Quality-of-Life AssessmentOTHER7NivolumabBIOLOGICAL6PembrolizumabBIOLOGICAL6CarboplatinDRUG5CisplatinDRUG5DocetaxelDRUG5Erlotinib HydrochlorideDRUG5PaclitaxelDRUG5Pemetrexed DisodiumDRUG5Questionnaire AdministrationOTHER4Gemcitabine HydrochlorideDRUG3PembrolizumabDRUG3Afatinib DimaleateDRUG2AzacitidineDRUG2Best PracticeOTHER2EntinostatDRUG2Gamma-Secretase Inhibitor RO4929097DRUG2Paclitaxel Albumin-Stabilized Nanoparticle FormulationDRUG2Positron Emission TomographyPROCEDURE2Recombinant EphB4-HSA Fusion ProteinBIOLOGICAL2Stereotactic Body Radiation TherapyRADIATION2Stereotactic Body Radiation Therapy (SBRT)RADIATION218F-FDGDRUG1

Trial status mix

COMPLETED32
TERMINATED9
WITHDRAWN5
ACTIVE_NOT_RECRUITING2
NOT_YET_RECRUITING1
RECRUITING1
UNKNOWN1

Phase mix

PHASE225
PHASE121
NA7
PHASE32
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.